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Abstract (250 words) 18 
Risk Factors and the Choice of Long-acting Reversible Contraception Following Medical 19 
Abortion – Effect on Subsequent Induced Abortion and Unwanted Pregnancy 20 
 21 
Objective: To analyse the post-abortion effect of long-acting reversible contraception (LARC) 22 
plans and initiation on the risk of subsequent unwanted pregnancy and abortion. 23 
Materials and methods: A retrospective cohort study of 666 women who underwent medical 24 
abortion between January–May 2013 at Helsinki University Hospital, Finland. Altogether 159 25 
(23.8%) women planning post-abortion use of levonorgestrel-releasing intrauterine system (LNG-26 
IUS) participated in a randomized study and had an opportunity to receive the LNG-IUS free-of-27 
charge from the hospital. The other 507(76.2%) women planned and obtained their contraception 28 
according to clinical routine. Demographics, planned contraception, and LARC initiation at the time 29 
of the index abortion were collected. Data on subsequent abortions were retrieved from the Finnish 30 
Abortion Register and electronic patient files until the end of 2014. 31 
Results: During the 21 months ([median], IQR 20–22) follow-up, 54(8.1%) women requested 32 
subsequent abortions. When adjusted for age, previous pregnancies, deliveries, induced abortions, 33 
and gestational-age, planning LARC for post-abortion contraception failed to prevent subsequent 34 
abortion (33 abortions/360 women,9.2%) compared to other contraceptive plans (21/306, 6.9%) 35 
(HR1.22, 95%CI 0.68–2.17). However, verified LARC initiation decreased the abortion rate (4 36 
abortions/177 women,2.3%) compared to women with uncertain LARC initiation status (50/489, 37 
10.2%) (HR0.17, 95%CI 0.06–0.48). When adjusted for LARC initiation status, age <25 years was a 38 
risk factor for subsequent abortion (27 abortions/283 women,9.5%) compared to women ≥25 years 39 
(27/383, 7.0%, HR1.95, 95%CI 1.04–3.67). 40 
Conclusions: Initiation of LARC as part of abortion service at the time of medical abortion is an 41 
important means to prevent subsequent abortion, especially among young women. 42 
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Recent estimates show that almost half of the pregnancies in the USA are unintended and about 50 
40% of them end up in abortion [1]. Induced abortion is often a consequence of inadequate 51 
contraception and the reasons not to use contraception originate from lack of correct information 52 
[2]. Women undergoing an induced abortion are at higher risk for a subsequent induced abortion 53 
[3]. Although abortion incidence has declined in the developed world [4,5], the rate of repeat 54 
abortion has not decreased [6]. In research studies, the reported rates of subsequent induced 55 
abortions have been 5%, 11%, and 20% at one, two, and four years after the index abortion, 56 
respectively [7,8]. The number of repeat induced abortions should be diminished, as they increase 57 
the risk of needing surgical interventions and preterm delivery [9,10–13]. Long-acting reversible 58 
contraceptives (LARC), including intrauterine devices (IUDs) and implants, are associated with the 59 
lowest incidence of subsequent abortion [3,14,15], especially if initiated at the time of the abortion 60 
[8,16,17]. 61 
 62 
Several interventions have been performed to increase the uptake of LARC after induced abortion. 63 
Contraceptive counselling alone has not increased LARC uptake [18]. Yet women are motivated to 64 
choose LARC at the time of abortion, especially if they have a recent history of induced abortion 65 
[19]. Studies suggest that the reduction of financial barriers may facilitate women to initiate LARC 66 
methods [20–23]. Also, minimizing the number of visits needed increases LARC uptake; the effect 67 
is well documented for surgical abortion [3,14,15,17,24,25]. However, increasing use of medical 68 
instead of surgical abortion has challenged the option to initiate LARC methods immediately. 69 
Initiation may be delayed 3-4 weeks after the abortion, if a conservative protocol is followed. 70 
Studies have shown that immediate insertion of the etonogestrel-implant shortly after mifepristone 71 
intake at the initial visit for abortion did not affect the efficacy of medical abortion, but increased 72 
the implant initiation rate [26,27]. Similar effects are evident in response to shortening the interval 73 
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between medical abortion and IUD insertion, and offering it as a part of abortion service [8,28,29]. 74 
We recently performed a randomized clinical trial that demonstrated the feasibility and safety of the 75 
fast-track (≤3 days) insertion of a levonorgestrel-releasing intrauterine system (LNG-IUS) during 76 
medical induced abortion [30,31]. Moreover, immediate insertion resulted in better one-year 77 
continuation rates than later LNG-IUS insertion [16]. 78 
 79 
In this cohort study we assessed factors affecting the selection and initiation of LARC for post-80 
abortion contraception at the time of medical induced abortion.  We also analysed the effect of 81 
planned vs. initiated contraception on the risks of subsequent unwanted pregnancy and induced 82 
abortion both for LARCs and for other contraceptives. 83 
 84 
Materials and Methods 85 
This retrospective cohort study analyses the effects of contraceptive plans and initiation after 86 
medical induced abortion. The study was performed in tandem with a randomized study assessing 87 
immediate vs. later provision of free-of-charge LNG-IUS (Mirena®, Bayer AG, Turku, Finland) 88 
[30,31]. The study population consisted of adult (≥ 18 years) women undergoing medical abortion 89 
up to 20 weeks of gestation during January 17th to May 20th 2013 at the Department of Obstetrics 90 
and Gynaecology of the Helsinki University Hospital, Finland. The recruitment for randomised 91 
controlled trial occurred after contraceptive counselling among women showing interest in LNG-92 
IUS contraception. During the study period all women showing interest in LNG-IUS contraception 93 
and meeting the inclusion criteria had an opportunity to participate to the study. 94 
 95 
Medical induced abortion was performed using oral mifepristone 200 mg and misoprostol 400 to 96 
800 mcg 1-3 days later according to the Finnish national guidelines [32]. Medical abortions up to 9 97 
6 
 
weeks of gestation (up to 63 days of amenorrhea) can be performed partially at home where 98 
misoprostol is self-administered by the patient. Later abortions were performed at the hospital ward.  99 
 100 
During the randomized trial [30,31] the LNG-IUS was offered either immediately (i.e. ≤3 days) or 101 
2–4 weeks after the abortion. If the woman did not participate in the trial, the LNG-IUS, copper-102 
IUD (Cu-IUD, Nova T380, Bayer Pharma AG, Berlin, Germany), or contraceptive implant 103 
(Nexplanon®, N.V. Organon, Oss, Netherlands) was offered from the hospital free-of-charge in 104 
cases of previous induced abortions. During the study period two cities of the hospital district, 105 
namely Helsinki and Vantaa, were offering the first contraceptive LNG-IUS, Cu-IUD, or implant 106 
free-of-charge, but the insertion occurred at the primary health care at a separate visit scheduled by 107 
the woman herself. These visits may be made up to three months after the first contact. We did not 108 
have access to information on these possible insertions. Thus, all verified LARC insertions in this 109 
study were free-of-charge. If the woman was planning other than LARC for post abortion 110 
contraception, a three-month start-up package of pills, patch, or ring was provided from the hospital 111 
liberally, but otherwise the patient had to buy contraception herself.  112 
 113 
Finnish law and guidelines on induced abortion, require contraceptive counselling before induced 114 
abortion [32]. Moreover, planned contraception, along with selected sociodemographic and 115 
abortion-related data are reported to the national Abortion Register. The register has been validated, 116 
and proven to be reliable and of high-quality [33,34].  117 
 118 
The abortion procedure in Finland consists of two visits: first visit occurring at the primary health 119 
care or private sector, and second at the hospital outpatient clinic. All women receive contraceptive 120 
counselling during both these visits, LARC presentation being an important part of the counselling. 121 
Data concerning planned contraception and background factors was collected as a part of the 122 
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randomized study, or from electronic patient records of the hospital system, and were completed 123 
from the Abortion Register. “LARC presented” is defined as LARC was recommended or presented 124 
to the woman and this was mentioned in the electronic patient files. “LARC planned” means that 125 
woman was recruited to the randomized study or the woman confirmed that LARC was planned for 126 
post-abortion contraception. “LARC initiated” means that initiation was verified as a part of the 127 
randomized study, or the insertion occurred in the hospital within one month following the abortion.   128 
 129 
Marital status was divided into categories of single, cohabiting, and married. Socio-economic status 130 
was presented as white-collar workers, blue-collar workers, students (level of education not 131 
defined), and other or not known according to the stated occupation or the highest education level 132 
reported. The coding was based on national standards (Statistics Finland). Ethnicity was available 133 
from the hospital files and is presented as groups of native Finnish and others. 134 
 135 
Information on subsequent pregnancies was derived from patient clinical records and The Finnish 136 
Abortion Register at the end of 2014. If woman was requesting subsequent abortion, but the 137 
pregnancy was diagnosed as a miscarriage or an ectopic, the pregnancy was defined as unwanted.  138 
 139 
This study was approved by the hospital system of Helsinki and Uusimaa, and National Institute of 140 
Health and Welfare. The clinical trial was approved by the local Ethics Committee and registered to 141 
www.clinicaltrials.gov (NCT01755715). 142 
 143 
Statistics 144 
Categorical data were analysed by cross tabulation and p-values calculated by Chi-square test. 145 
Kaplan-Meier analysis and Log-Rank test was used to describe subsequent unwanted pregnancies. 146 
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Survival analysis and hazard ratios were analysed by Cox’s regression model. All analyses were 147 
performed with IBM SPSS statistical software version 24.   148 
 149 
Results 150 
Study Population 151 
Total of 666 women underwent medical abortion, representing 92.2% of all women undergoing an 152 
induced abortion during the study period (Figure 1). Demographics of the women are presented in 153 
Table 1. Most women were 20 to 35 years old, of normal weight and half of them smoked regularly. 154 
Almost 60% of them had a history of previous pregnancy and one third a history of induced 155 
abortion. Three out of four underwent early medical abortion (gestational age ≤63 days) and one out 156 
of four participated in the randomized trial. Detailed demographics of the women participating in 157 
the randomized study have been published previously [30, 31]. Briefly, women participating in the 158 
randomized trial (n=159) compared to non-RCT-women (n=507) in this cohort belonged to older 159 
age-groups (21–24 year olds 33 [20.8%] vs. 132 [26.0%]; 25–29 year olds 47 [29.6%] vs. 94 160 
[18.5%], other groups data not shown, p=0.02), had more often history of previous pregnancy (113 161 
[71.1%] vs. 282 [55.6%], p=0.001), delivery (91 [57.2%] vs. 205 [40.4%], p<0.001) and induced 162 
abortion (70 [44.0%] vs. 159 [31.4%], p=0.003), and they requested the abortion at later gestational-163 
age (≤63 days 108 [67.9%] vs. 399 [78.7%], 64–84 days 43 [27.0%] vs. 93 [18.3%], ≥ 85 days 8 164 
[5.0%] vs. 15 [3.0%], p=0.02). 165 
 166 
Presentation, Planning, and Insertion of Post-abortal LARC 167 
Long-acting contraception was presented to 429 (64.4%) women (Table 2). LARC was presented 168 
more often to women older than 25 years than to women younger than 25 years of age (271/383 169 
[70.8%] vs. 158/283 [55.8%] risk ratio [RR] 1.27, 95% confidence interval [95%CI] 1.12–1.43, 170 
p<0.001). Furthermore, LARC was presented more often to women who were obese and married or 171 
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cohabiting, had history of pregnancy, delivery or induced abortion, and were requesting second 172 
trimester abortion. 173 
 174 
After the counselling, 360 (54.0%) women were planning initiation of post abortion LARC (Figure 175 
1, Table 2). The most popular method was the LNG-IUS (n=268, 74.4%) and 159 (59.3%) of these 176 
women participated in the randomized study. Contraindication for progestin-containing 177 
contraception was present in only one woman (newly diagnosed breast cancer), whereas 178 
contraindications for intrauterine contraception occurred in four cases (one case of acute 179 
gonorrhoea, two cases of submucosal myomas and one uterus bicornus).   180 
 181 
Altogether 177 (26.6%) women received LARC at the time or within 4 weeks of medical induced 182 
abortion. This represented 49.2% of all women planning LARC. Among the 159 women who 183 
participated in the randomized controlled trial 141 (88.7%) received the LNG-IUS. None of the 184 
women planning other forms of contraception received LARC. Most of these LARCs were LNG-185 
IUSs (n=149, 84.2%) followed by implants (n=27, 15.3%) and one Cu-IUD. Even though LARC 186 
was planned more often for women older than 25 years, it was initiated similarly in younger and in 187 
older women (Table 2). Women with a history of previous pregnancy (either delivery or abortion) 188 
initiated a LARC more often than women with no such history. Abortion conducted at the hospital 189 
ward (late first-trimester or second trimester abortion) increased the uptake of LARC. Regardless of 190 
plans, native Finnish women initiated LARC more often than women of other ethnic groups. Only 191 
36 of 201 (17.9%) women who planned LARC but did not participate in the randomized study 192 






Subsequent Abortion and Unwanted Pregnancy 197 
The median follow-up time was 649 days (IQR 614–679) (i.e. 21 months [20–22]). During the 198 
follow-up, altogether 54 women (8.1%) underwent a subsequent induced abortion. The median time 199 
to subsequent abortion was 336 days (246–450) (i.e. 11 months [8–15]). According to the patient 200 
files, there were five additional unwanted pregnancies: three women were diagnosed with 201 
miscarriage at the time they were requesting subsequent abortion; one woman had an ectopic 202 
pregnancy following the use of emergency contraception; and one pregnancy was diagnosed during 203 
oral contraceptive use following fibroid resection. Table 3 presents the distribution and hazard 204 
ratios of subsequent abortions and unwanted pregnancies according to selected risk factors, and 205 
LARC planning and initiation status. After adjustments, only initiated LARC decreased the rate of 206 
subsequent abortion (hazard ratio [HR] 0.17, 95% confidence interval [95% CI] 0.06–0.48, 207 
p=0.0008) and unwanted pregnancy (HR 0.15, 95% CI 0.05–0.43, p=0.0004).  Four unwanted 208 
pregnancies occurred in women who participated in the randomized trial following initiation of 209 
LNG-IUS use. One pregnancy was recognized after an unnoticed expulsion, two LNG-IUSs were 210 
removed before the subsequent pregnancy, and one abortion was performed in a case where LNG-211 
IUS had been inserted, but the patient never returned for follow-up. Age under 25 years remained 212 
an independent risk factor for both subsequent induced abortion and unwanted pregnancy even after 213 
adjusting LARC initiation status. Kaplan-Meier survival curves (Figure 2) display the effect of 214 
LARC initiation status on subsequent unwanted pregnancy. Verified initiation of LARC reduced the 215 
occurrence of subsequent unwanted pregnancy significantly during the follow-up. Conversely, 216 
planned but not initiated LARC resulted more often in unwanted pregnancy when compared to 217 







Findings and Interpretation 223 
We found that during the nearly two years of follow-up, only initiated LARC decreased the need for 224 
subsequent abortion and unplanned pregnancy, when compared to only planning of LARC, or 225 
initiation of other contraceptive methods at the time of the abortion. Age less than 25 years was an 226 
independent risk factor for subsequent abortion and unwanted pregnancy. 227 
 228 
Previous studies have shown that young age, second trimester abortion, and history of previous 229 
pregnancy, delivery, and induced abortion are risk factors for subsequent induced abortion [3, 35, 230 
36,37]. LARC methods are the most effective in prevention of unintended pregnancy and subsequent 231 
abortion [3,14]. For example, the contraceptive CHOICE project in the U.S. has shown counselling 232 
that highlights   LARC methods to be the most effective, and removing cost and access barriers can 233 
increase LARC initiation rates and reduce both total and repeat abortion rates [21,38]. The CHOICE 234 
investigators estimated that contraceptive policy facilitating LARC initiation could prevent up to 41% 235 
to 71% of abortions performed annually in the U.S. [21]. LARC methods have long been liberally 236 
recommended to all women in our clinic in need of contraception. However, in this study information 237 
concerning contraceptive counselling and LARC recommendations is based on retrospective data 238 
collected from patient files. Because of the clinic’s long-standing tradition and parallel RCT 239 
recruitment, LARCs may have been discussed more often than recorded in the patient files. Even 240 
though we recommended and presented LARC more often to women older than 25 years of age 241 
compared to younger women, we initiated LARC similarly to both age groups. We speculate this was 242 
mostly due to easy and cost-free access to LNG-IUS insertion as part of the randomized study.  243 
 244 
A key finding of this study is that only planning LARC does not decrease the need for subsequent 245 
abortion. In contrast, the need for effective contraception was highest in this group. However, this 246 
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may be due to the fact that women with an increased risk of subsequent abortion were successfully 247 
identified and plans to initiate LARC were made. But, as the plans did not lead to LARC initiation, 248 
this resulted in the highest need for another abortion in this group. 249 
 250 
This study has practical implications. It shows that the policy of only discussing LARC, not leading 251 
into LARC initiation, is not effective. This is likely to be associated with the high up-font cost of 252 
LARC methods and structure of the contraceptive service delivery system. None of the women 253 
studied were willing or able to buy LARC beforehand even though this option is available.  We are 254 
pleased to note discussion about possible free-of-charge provision of contraception, including 255 
LARC, is currently on-going in Finland [39]. 256 
 257 
Strengths and Weaknesses of the Study 258 
The predominant strength of our analysis is that the study population is well representative of the 259 
average Finnish woman seeking abortion; in 2013, the incidence of abortion in Finland was highest 260 
among women aged 20–24 years (of the study population 25% were 20–24 years of age), 36% had 261 
experienced abortion previously (study population 34%), and 49% had a previous delivery (study 262 
population 44%) [40].  263 
 264 
The setting of this study may be retrospective, but the important background characteristics are 265 
reliable and could be identified from the hospital records as they are routinely asked. In the Finnish 266 
healthcare setting, induced abortions are almost always treated in public health care (<6% in private 267 
clinics) (Anna Heino, National Institute for Health and Welfare, personal communication, March 268 
26, 2016) [41]. In addition, the data concerning induced abortions are accurate and reliable, thus 269 
induced abortions can be identified from the Abortion Register [33,34]. Data on additional 270 
unwanted pregnancies was derived from the hospital patient files only, and may thus be 271 
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underestimated. According to Kaplan-Meier analysis (Figure 2), more accurate detection of 272 
unwanted pregnancies would have increased the differences between the initiated or planned LARC 273 
and other contraceptive plans. 274 
 275 
However, a weakness of the study is that we have no information concerning the LARC initiation 276 
status in the group of women that planned LARC, but it was not initiated at the hospital. This is due 277 
to the fact that women came from several communities with different electronic patient file systems 278 
for which we had no access. Also, some of the LARCs might have been initiated by private 279 
physicians. Furthermore, all boundaries to access of effective contraception in primary healthcare 280 
could not be analysed. For example, it was unknown whether women attended a planned follow-up 281 
visit at primary health care. Previous studies from our group [42] and elsewhere [43] have shown 282 
that up to half of the women do not attend the scheduled post-abortion follow-up. 283 
 284 
Conclusion 285 
Fast-tract and easy access initiation of LARC as part of the abortion service provided at the time of 286 
the medical abortion is an important means to prevent subsequent abortion, especially among young 287 
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Figure 1. The formation of the study group of 666 women undergoing medically induced abortion 441 
and their planned contraception during January 17th to May 20th 2013.  442 




  445 
b) 446 
  447 
 448 
Log-Rank test p<0.0001 
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Figure 2. Kaplan-Meier survival without subsequent unwanted pregnancy among 666 women 449 
requesting medical abortion during January 17th to May 20th 2013. 450 
a) According to initiation status of long-acting reversible contraception (LARC).  451 
b) According to verified LARC insertion, planning but not necessarily starting LARC, or other 452 
contraceptive plans at the time of index abortion. 453 
Median follow-up time was 649 days (interquartile range 614–679, i.e. 21 months [20–22]). 454 
 455 
  456 
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Table 1. Demographics of the 666 women undergoing medical induced abortion during January 457 
17th to May 20th 2013. Data are presented as n (%) unless stated other vice. 458 
  
Age (years) (median [IQR])                  26.0 (22.0–32.0) 
Age groups  
   ≤ 20 years 118 (17.7%) 
   21 to 24 years 165 (24.8%) 
   25 to 29 years 141 (21.2%) 
   30 to 34 years 124 (18.6%) 
   35 to 39 years 84 (12.6%) 
   ≥ 40 years 34 (5.1%) 
Body mass index (kg/m2) (missing n=90 [13.5%]) (median [IQR]) 22.7 (20.7–25.6) 
   Normal weight (body mass index <25 kg/m2) 413 (62.0%) 
Regular smoking (missing n=17 [2.6%]) 308 (46.2%) 
Regular use of alcohol (missing n=59 [8.9%]) 407 (61.1%) 
Socioeconomic status  
   White collar workers 130 (19.5%) 
   Blue collar workers 235 (35.3%) 
   Students 163 (24.5%) 
   Others or not known 138 (20.7%) 
Marital status (missing n=14 [2.1%])  
   Married or cohabiting 272 (40.8%) 
   Single 380 (57.1%) 
Ethnicity native Finnish 513 (77.0%) 
Residence Helsinki or Vantaa* 517 (77.6%) 
Previous pregnancy 395 (59.3%) 
Previous delivery 296 (44.4%) 
Previous vaginal delivery 272 (40.8%) 
Previous cesarean section 45 (6.8%) 
Previous induced abortion 229 (34.4%) 
Previous misscarriage 97 (14.6%) 
Gestational age (median [IQR]) 54 (47–63) 
   ≤63 days 507 (76.1%) 
   64–84 days 136 (20.4%) 
   ≥85 days 23 (3.5%) 
Abortion partially at home among gestational age of ≤63 days 437 (86.2%) 
 459 
* Cities offering a first intrauterine device or system or implant free of costs 460 
  461 
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Table 2. LARC presented, planned, and inserted according to selected demographic factors among 462 
666 women undergoing medical abortion during January 17th to May 20th 2013. 463 
 n LARC presented^  p-value LARC planned^  p-value LARC inserted^  p-value 
Age        
   <25 years 283 158 (55.8%) <0.001 135 (47.7%) 0.005 66 (23.3%) 0.10 
   ≥25 years 383 271 (70.8%)  225 (58.7%)  111 (29.0%)  
Body mass index (kg/m2)      
   <25  413 273 (66.1%) <0.001 228 (55.2%) <0.001 112 (27.1%) 0.006 
   25-30  108 65 (60.2%)   53 (49.1%)   32 (29.6%)   
   ≥30  55 46 (83.6%)   42 (76.4%)   21 (38.2%)   
   Not known  90 45 (50.0%)   37 (41.1%)   12 (13.3%)   
Socioeconomic status        
   White collar workers  130 83 (63.8%) 0.08 67 (51.5%) 0.15 34 (26.2%) 0.08 
   Blue collar workers  235 164 (69.8%)   141 (60.0%)   73 (31.1%)   
   Students  163 93 (57.1%)   84 (51.5%)   44 (27.0%)   
   Others or not known  138 89 (64.5%)   68 (49.3%)   26 (18.8%)   
Marital status        
   Married or cohabiting  272 193 (71.0%) 0.002 159 (58.5%) 0.049 72 (26.5%) 0.38 
   Single  380 224 (58.9%)   191 (50.3%)   99 (26.1%)   
   Not known  14 12 (85.7%)   10 (71.4%)   6 (42.9%)   
Ethnicity        
   Native Finnish  513 327 (63.7%) 0.51 273 (53.2%) 0.43 147 (28.7%) 0.026 
   Other  153 102 (66.7%)   87 (56.9%)   30 (19.6%)   
Residence        
   Helsinki or Vantaa*  517 336 (65.0%) 0.56 281 (54.4%) 0.77 137 (26.5%) 0.93 
   Other  149 93 (62.4%)   79 (53.0%)   40 (26.8%)   
Previous pregnancy        
   Yes  395 305 (77.2%) <0.001 256 (64.8%) <0.001 131 (33.2%) <0.001 
   No  271 124 (45.8%)   104 (38.4%)   46 (17.0%)   
Previous delivery        
   Yes  296 236 (79.7%) <0.001 202 (68.2%) <0.001 98 (33.1%) 0.001 
   No  370 193 (52.2%)   158 (42.7%)   79 (21.4%)   
Previous induced abortion      
   Yes  229 182 (79.5%) <0.001 149 (65.1%) <0.001 81 (35.4%) <0.001 
   No  437 247 (56.5%)   211 (48.3%)   96 (22.0%)   
Gestational-age group        
   ≤63 days  507 318 (62.7%) 0.047 265 (52.3%) 0.040 114 (22.5%) <0.001 
   64-84 days  136 91 (66.9%)   77 (56.6%)   48 (35.3%)   
   ≥85 days  23 20 (87.0%)   18 (78.3%)   15 (65.2%)   
Early medical abortion (≤63 days)      
   Yes  507 318 (62.7%) 0.10 265(52.3%) 0.10 114 (22.5%) <0.001 
   No  159 111 (69.8%)  95 (59.7%)  63 (39.6%)  
Abortion partially at home among gestation of ≤63 days     
   Yes  437 272 (62.2%) 0.58 226 (51.7%) 0.53 89 (20.4%) 0.004 
   No  70 46 (65.7%)   39 (55.7%)   25 (35.7%)   
Participated in randomized trial       
   Yes  159 159 (100.0%) <0.001 159 (100.0%) <0.001 141 (88.7%) <0.001 
   No  507 270 (53.3%)   201 (39.6%)   36 (7.1%)   
 ^ ‘LARC presented’ was defined as it was recommended or presented to the woman and mentioned 464 
in the electronic patient file. ‘LARC planned’ means that woman was recruited to the randomized 465 
26 
 
study or LARC was planned otherwise to post abortion contraception. ‘LARC initiated’ means that 466 
initiation was verified as a part of the randomized study or insertion occurred in a hospital within 467 
one month following the abortion. 468 
* Cities offering the first long-acting reversible contraceptives free-of-cost to their citizens. 469 
  470 
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Table 3: Risk factors of subsequent abortion and unwanted pregnancy during the follow-up (median 21 months, interquartile range 20–22 months) 
among 666 women undergoing medical induced abortion during January 17th to May 20th 2013. Cox regression model. 
 
 
Subsequent abortion Subsequent abortion or unwanted pregnanacy  
n (%) Unadjusted HR 
(95%CI) 
p-value Adjusted HR 
(95%CI) 
p-value n (%) Unadjusted HR 
(95%CI) 




Planned other contraception (n=306) 21 (6.9%) Reference  Reference*  25 (8.2%) Reference  Reference*  
Planned LARCa (n=360) 33 (9.2%) 1.37 (0.79–2.37) 0.26 1.22 (0.68–2.17) 0.51 34 (9.4%) 1.19 (0.71–2.00) 0.51 1.02 (0.59–1.76) 0.95 
Planned other contraception (n=306) 21 (6.9%) Reference  Reference*  25 (8.2%) Reference  Reference*  
LARC planned, not inserted (n=183) 29 (15.8%) 2.47 (1.41–4.33) 0.002 2.22 (1.23–3.98) 0.008 30 (16.4%) 2.15 (1.27–3.66) 0.005 1.86 (1.07–3.24) 0.028 
LARC inserted (n=177) 4 (2.3%) 0.33 (0.11–0.95) 0.04 0.26 (0.08–0.77) 0.015 4 (2.3%) 0.27 (0.10–0.79) 0.016 0.21 (0.07–0.62) 0.005 
LARC not inserted (n=489) 50 (10.2%) Reference  Reference*  55 (11.2%) Reference  Reference*  
LARC inserted (n=177) 4 (2.3%) 0.21 (0.08–0.59) 0.003 0.17 (0.06–0.48) <0.001 4 (2.3%) 0.19 (0.07–0.54) 0.002 0.15 (0.05–0.43) <0.001 
           








<25 (n=283) 27 (9.5%) 1.34 (0.79–2.29) 0.28 1.95 (1.04–3.67) 0.04 28 (9.9%) 1.22 (0.73–2.03) 0.45 1.84 (1.00–3.38) 0.049 








Has previous pregnanacy (n=395) 36 (9.1%) 1.38 (0.78–2.43) 0.26 1.81 (0.63–5.19) 0.27 40 (10.1%) 1.45 (0.84–2.51) 0.18 1.49 (0.53–4.21) 0.45 








Has previous delivery (n=296) 29 (9.8%) 1.48 (0.86–2.52) 0.15 1.63 (0.65–4.10) 0.30 33 (11.1%) 1.62 (0.97–2.70) 0.07 1.95 (0.80–4.80) 0.14 








Has previous induced abortion (n=229) 17 (7.4%) 0.86 (0.48–1.53) 0.61 0.75 (0.37–1.53) 0.43 20 (8.7%) 0.96 (0.56–1.64) 0.88 0.88 (0.46–1.72) 0.72 








64-84 days (n=136) 12 (8.8%) 1.09 (0.57–2.08) 0.79 1.15 (0.59–2.21) 0.68 13 (9.6%) 1.06 (0.57–1.98) 0.85 1.12 (0.60–2.10) 0.72 
≥85 days (n=23) 3 (13.0%) 1.65 (0.51–5.34) 0.40 2.73 (0.82–9.09) 0.10 3 (13.0%) 1.49 (0.46–4.81) 0.50 2.60 (0.78–8.62) 0.12 
 
a Long-acting reversible contraception (copper-containing intrauterine device, levonorgestrel-releasing intrauterine system and implant)   
* Adjusted by age (<25 years vs. ≥25 years), previous pregnancy (yes vs. no), previous delivery (yes vs. no), previous induced abortion (yes vs. no) and 
gestational-age groups (≤63 days vs. 64-84 days vs. ≥85 days. 
^ Adjusted by factors mentioned above and LARC insertion status (inserted vs. not inserted). 
 
